Selpercatinib, also known by its brand name Retevmo, is a targeted therapy medication used in the treatment of certain types of cancer. Specifically, it is approved for the treatment of non-small cell lung cancer, medullary thyroid cancer, and other types of solid tumors that have a specific genetic mutation known as RET fusion.

This medication works by targeting and inhibiting the activity of the RET protein, which is often overactive in cancer cells with the RET fusion mutation. By blocking this protein, selpercatinib helps to slow down or stop the growth and spread of cancer cells, ultimately leading to tumor shrinkage and improved outcomes for patients.

It is important to note that selpercatinib is a prescription medication and should only be taken under the guidance and supervision of a qualified healthcare provider. Your doctor will determine the appropriate dosage and treatment schedule based on your individual medical history, the type and stage of your cancer, and other factors.

As with any medication, selpercatinib may cause side effects in some patients. Common side effects may include fatigue, diarrhea, nausea, and changes in liver function tests. It is important to report any side effects to your healthcare provider so that they can be properly managed.

Overall, selpercatinib has shown promising results in the treatment of certain types of cancer, particularly those with the RET fusion mutation. If you have been diagnosed with a cancer that may benefit from this medication, talk to your doctor about whether selpercatinib may be a suitable treatment option for you.